Upgrade to SI Premium - Free Trial

Vanda Pharmaceuticals (VNDA) Reports Q2 EPS of $0.21, Revenues Beat; Offers FY19 HETLIOZ & Fanapt Combined Sales Outlook

July 31, 2019 5:31 PM
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.21, versus $0.00 reported last year. Revenue for the quarter came in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Earnings Guidance Management Comments

Next Articles